e-learning
resources
Glasgow 2004
Sunday 05.09.2004
New and emerging pharmacological strategies in the treatment of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical improvements in patients with latex - induced asthma treated with RuzamÔ
G. Kazakova, O. Vasilyeva, N. Kolganova (Moscow, Russia)
Source:
Annual Congress 2004 - New and emerging pharmacological strategies in the treatment of asthma
Session:
New and emerging pharmacological strategies in the treatment of asthma
Session type:
Poster Discussion
Number:
1395
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Kazakova, O. Vasilyeva, N. Kolganova (Moscow, Russia). Clinical improvements in patients with latex - induced asthma treated with RuzamÔ. Eur Respir J 2004; 24: Suppl. 48, 1395
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Clinical, functional and laboratory assessment of treatment efficacy in COPD patients
Source: International Congress 2014 – Predictors
Year: 2014
Effect of allergic sensitization on clinical course of patients with COPD in the Hokkaido COPD cohort study
Source: International Congress 2014 – COPD physiopathology
Year: 2014
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
The parameters that may affect inhalation therapy success in elderly COPD and asthma patients
Source: International Congress 2015 – Co-existing diseases and asthma
Year: 2015
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Usefulness of induced sputum eosinophil count to assess severity and treatment outcome in asthma patients
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013
Characteristics of asthma patients responding to anti-IgE therapy
Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Year: 2013
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Improvement of control and quality of life in severe allergic asthmatics patients treated with omalizumab
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008
Clinical characteristics of asthma patients with small airway dysfunction
Source: Virtual Congress 2020 – Unusual tools for evaluating obstructive diseases
Year: 2020
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Evolution of patients with severe asthma treated with mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Effects of Omalizumab treatment on nasal symptoms (SNOT score) in patients treated for severe asthma.
Source: International Congress 2017 – Asthma management
Year: 2017
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Relationship between asthma control test (ACT) and clinical, functional and inflammatory markers in treated and non treated asthmatics
Source: Annual Congress 2008 - Inflammatory biomarkers
Year: 2008
Clinical characteristics and disease control of US asthma patients treated in specialty clinics
Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept